Shire Submits Investigational New Drug Application

July 6, 2017

Shire said Thursday it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for SHP654, a gene therapy for the treatment of hemophilia A. Shire said the drug aims to provide long-term protection for hemophilia A patients, and gene therapy also holds promise for hemophilia B populations,

Shire said the IND filing for SHP654 was based on the results of pre-clinical and phase 1 studies demonstrating the potential utility of the therapy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

By Bryan Smith

Free Email Newsletter


Enter your email address below to get the latest news and analysts' ratings for your stocks with MarketBeat's FREE daily email newsletter: